STOCK TITAN

Atricure Financials

ATRC
Trailing 12 months to June 30, 2026
Revenue $569.6M +13.9% YoY
Net Income $10.6M +129.0% YoY
EPS (Diluted) $0.21 +127.3% YoY
Free Cash Flow $53.1M +110.0% YoY
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Atricure (ATRC) reported $569.6M in revenue over the twelve months to Jun 30, 2026, up 13.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATRC FY2025

AtriCure’s dominant mechanic is revenue expansion finally converting into cash while operating costs still delay reported profitability.

From FY2022 through FY2025, gross margin stayed structurally stable near 75.0% while operating margin improved from -12.9% to -1.8%, showing that the recovery is occurring below gross profit rather than through a major change in product economics. Revenue growth has increasingly absorbed the operating platform: operating expenses rose in dollars, yet consumed a smaller share of sales, narrowing the loss without abandoning continued R&D investment.

The clearest earnings-quality shift is that operating cash flow turned positive in FY2023 and reached $57M in FY2025 while net income remained -$11M. Free cash flow likewise moved from negative in FY2023 to positive in FY2024 and FY2025, so recent cash generation is being supported by non-cash charges and balance-sheet timing before accounting profitability arrives.

A conservative financing posture—debt-to-equity of 0.1x and current ratio of 4.0x in FY2025—has funded expansion without heavy debt dependence. Capital expenditures fell from $16.9M in FY2022 to $9.1M in FY2025, reducing the cash reinvestment burden as free cash flow turned positive.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 59 / 100
Financial Health Score 59/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Atricure's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
22

Atricure has an operating margin of -1.8%, meaning the company loses $2 on every $100 of revenue. This results in a profitability score of 22/100. This is up from -8.6% the prior year.

Growth
77

Atricure's revenue grew 14.9% year-over-year to $534.5M, a solid pace of expansion. This earns a growth score of 77/100.

Leverage
99

Atricure carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
86

With a current ratio of 3.96, Atricure holds $3.96 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 86/100.

Cash Flow
44

Atricure has a free cash flow margin of 9.0%, earning a moderate score of 44/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
23

Atricure posts a -2.3% return on equity (ROE), meaning it loses $2 for every $100 of shareholders' equity. This results in a returns score of 23/100. This is up from -9.7% the prior year.

Altman Z-Score Safe
9.46

Atricure scores 9.46, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.5B) relative to total liabilities ($162.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
7/9

Atricure passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed
N/A

Atricure reported a net loss of $11.4M while generating $57.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Atricure reported an operating loss of $9.4M against $5.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$534.5M
YoY+14.9%
5Y CAGR+20.9%
10Y CAGR+15.2%

Atricure generated $534.5M in revenue in fiscal year 2025. This represents an increase of 14.9% from the prior year.

EBITDA
$12.1M
YoY+160.0%

Atricure's EBITDA was $12.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 160.0% from the prior year.

Net Income
-$11.4M
YoY+74.4%

Atricure reported -$11.4M in net income in fiscal year 2025. This represents an increase of 74.4% from the prior year.

EPS (Diluted)
-$0.24
YoY+74.7%

Atricure earned -$0.24 per diluted share (EPS) in fiscal year 2025. This represents an increase of 74.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$48.3M
YoY+6381.1%

Atricure generated $48.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 6381.1% from the prior year.

Cash & Debt
$167.4M
YoY+36.4%
5Y CAGR+31.9%
10Y CAGR+21.6%

Atricure held $167.4M in cash against $61.9M in long-term debt as of fiscal year 2025.

Shares Outstanding
50M
YoY+1.9%
5Y CAGR+1.8%
10Y CAGR+4.4%

Atricure had 50M shares outstanding in fiscal year 2025. This represents an increase of 1.9% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
75.0%
YoY+0.3pp
5Y CAGR+2.7pp
10Y CAGR+3.4pp

Atricure's gross margin was 75.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the prior year.

Operating Margin
-1.8%
YoY+6.8pp
5Y CAGR+19.7pp
10Y CAGR+18.8pp

Atricure's operating margin was -1.8% in fiscal year 2025, reflecting core business profitability. This is up 6.8 percentage points from the prior year.

Net Margin
-2.1%
YoY+7.5pp
5Y CAGR+21.2pp
10Y CAGR+18.8pp

Atricure's net profit margin was -2.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.5 percentage points from the prior year.

Return on Equity
-2.3%
YoY+7.4pp
5Y CAGR+9.3pp
10Y CAGR+12.3pp

Atricure's ROE was -2.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.4 percentage points from the prior year.

Capital Allocation

R&D Spending
$99.2M
YoY+3.2%
5Y CAGR+18.2%
10Y CAGR+14.4%

Atricure invested $99.2M in research and development in fiscal year 2025. This represents an increase of 3.2% from the prior year.

Capital Expenditures
$9.1M
YoY-21.0%
5Y CAGR+11.5%
10Y CAGR-3.9%

Atricure invested $9.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 21.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

ATRC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATRC quarterly income statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue$153.6M+8.7%$141.2M+0.5%$140.5M+4.6%$134.3M-1.4%$136.1M+10.1%$123.6M-0.5%$124.3M+7.2%$115.9M
Cost of Revenue$35.0M+9.5%$31.9M-9.2%$35.2M+6.8%$32.9M-5.0%$34.7M+11.8%$31.0M-2.1%$31.7M+8.7%$29.1M
Gross Profit$118.6M+8.5%$109.3M+3.8%$105.3M+4.0%$101.3M-0.1%$101.5M+9.6%$92.6M0.0%$92.6M+6.7%$86.8M
R&D Expenses$26.4M+8.9%$24.2M-1.1%$24.5M+7.0%$22.9M-21.8%$29.3M+30.0%$22.5M-35.6%$35.0M+66.8%$21.0M
SG&A Expenses$82.6M-2.4%$84.5M+7.9%$78.3M+0.1%$78.2M-0.2%$78.4M+3.1%$76.1M+5.4%$72.2M-1.4%$73.2M
Operating Income$9.7M+1737.5%$526K-78.9%$2.5M+1097.6%$208K+103.4%-$6.2M-4.0%-$6.0M+59.0%-$14.5M-96.1%-$7.4M
Interest Expense$1.3M-1.6%$1.3M-10.9%$1.5M+2.5%$1.5M-1.5%$1.5M+5.2%$1.4M-2.4%$1.5M-13.0%$1.7M
Income Tax$471K+64.7%$286K-52.6%$604K+233.7%$181K-30.7%$261K+9.2%$239K-10.2%$266K-17.4%$322K
Net Income$9.0M+8191.7%$108K-93.8%$1.8M+757.7%-$267K+95.7%-$6.2M+8.3%-$6.7M+56.7%-$15.6M-98.2%-$7.9M
EPS (Diluted)$0.18$0.00-100.0%$0.04-$0.01-$0.13+7.1%-$0.14+57.6%-$0.33-94.1%-$0.17

ATRC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATRC quarterly balance sheet
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Total Assets$676.6M+5.1%$644.0M-1.6%$654.2M+2.9%$635.4M+4.4%$608.8M+2.9%$591.6M-2.9%$609.3M-0.9%$615.1M
Current Assets$345.5M+10.1%$313.7M-2.7%$322.5M+7.1%$301.1M+11.0%$271.3M+7.9%$251.5M-6.1%$267.8M-0.5%$269.3M
Cash & Equivalents$167.8M+14.8%$146.2M-12.7%$167.4M+13.2%$147.9M+25.5%$117.8M+17.9%$99.9M-18.6%$122.7M-5.8%$130.3M
Inventory$83.9M+3.4%$81.1M+3.4%$78.5M-0.6%$79.0M+3.4%$76.3M+1.9%$74.9M-0.6%$75.3M-1.6%$76.5M
Accounts Receivable$80.0M+12.2%$71.3M+7.0%$66.7M+5.8%$63.0M-4.6%$66.0M+4.2%$63.3M+4.9%$60.3M+9.9%$54.9M
Goodwill$234.8M0.0%$234.8M0.0%$234.8M0.0%$234.8M0.0%$234.8M0.0%$234.8M0.0%$234.8M0.0%$234.8M
Total Liabilities$160.2M+5.2%$152.3M-6.1%$162.2M+2.1%$158.9M+10.1%$144.4M+5.4%$137.0M-7.6%$148.4M-1.1%$150.0M
Current Liabilities$81.9M+11.9%$73.2M-10.2%$81.5M+4.7%$77.8M+13.1%$68.8M+12.4%$61.2M-16.6%$73.4M-1.4%$74.4M
Long-Term Debt$61.0M0.0%$61.0M-1.4%$61.9M0.0%$61.9M0.0%$61.9M0.0%$61.9M0.0%$61.9M0.0%$61.9M
Total Equity$516.4M+5.0%$491.7M0.0%$491.9M+3.2%$476.5M+2.6%$464.5M+2.2%$454.6M-1.4%$461.0M-0.9%$465.0M
Retained Earnings-$404.1M+2.2%-$413.1M0.0%-$413.2M+0.4%-$415.0M-0.1%-$414.7M-1.5%-$408.5M-1.7%-$401.8M-4.0%-$386.2M

ATRC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATRC quarterly cash flow statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Operating Cash Flow$22.2M+655.4%-$4.0M-120.0%$20.0M-25.0%$26.7M+23.6%$21.6M+296.1%-$11.0M-288.9%$5.8M-70.8%$20.0M
Capital Expenditures$3.8M-2.2%$3.9M+140.4%$1.6M-38.5%$2.6M-2.1%$2.7M+22.1%$2.2M-19.0%$2.7M-25.4%$3.6M
Free Cash Flow$18.4M+334.8%-$7.8M-142.6%$18.4M-23.6%$24.1M+27.2%$19.0M+243.5%-$13.2M-520.2%$3.1M-80.8%$16.4M
Investing Cash Flow-$3.8M+2.2%-$3.9M-48.0%-$2.6M+0.1%-$2.6M+66.0%-$7.7M-355.8%-$1.7M+88.6%-$14.7M-434.5%$4.4M
Financing Cash Flow$3.3M+124.6%-$13.3M-731.8%$2.1M-64.9%$6.0M+75.0%$3.4M+133.1%-$10.3M-694.1%$1.7M+621.9%-$333K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATRC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

ATRC quarterly financial ratios
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Gross Margin77.2%-0.2pp77.4%+2.4pp75.0%-0.5pp75.5%+0.9pp74.5%-0.4pp74.9%+0.4pp74.5%-0.4pp74.9%
Operating Margin6.3%+5.9pp0.4%-1.4pp1.8%+1.6pp0.1%+4.7pp-4.5%+0.3pp-4.8%+6.9pp-11.7%-5.3pp-6.4%
Net Margin5.8%+5.8pp0.1%-1.2pp1.3%+1.5pp-0.2%+4.3pp-4.5%+0.9pp-5.5%+7.1pp-12.5%-5.8pp-6.8%
Return on Equity1.7%+1.7pp0.0%-0.3pp0.4%+0.4pp-0.1%+1.3pp-1.3%+0.2pp-1.5%+1.9pp-3.4%-1.7pp-1.7%
Return on Assets1.3%+1.3pp0.0%-0.3pp0.3%+0.3pp0.0%+1.0pp-1.0%+0.1pp-1.1%+1.4pp-2.5%-1.3pp-1.3%
Current Ratio4.22-0.1x4.29+0.3x3.96+0.1x3.87-0.1x3.94-0.2x4.11+0.5x3.650.0x3.62
Debt-to-Equity0.120.0x0.120.0x0.130.0x0.130.0x0.130.0x0.140.0x0.130.0x0.13
FCF Margin12.0%+17.6pp-5.6%-18.7pp13.1%-4.9pp18.0%+4.0pp13.9%+24.6pp-10.7%-13.2pp2.5%-11.6pp14.1%

Similar Companies

Frequently Asked Questions

What is Atricure's annual revenue?

Atricure (ATRC) reported $534.5M in total revenue for fiscal year 2025. This represents a 14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Atricure's revenue growing?

Atricure (ATRC) revenue grew by 14.9% year-over-year, from $465.3M to $534.5M in fiscal year 2025.

Is Atricure profitable?

No, Atricure (ATRC) reported a net income of -$11.4M in fiscal year 2025, with a net profit margin of -2.1%.

Atricure (ATRC) reported diluted earnings per share of -$0.24 for fiscal year 2025. This represents a 74.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atricure (ATRC) had EBITDA of $12.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Atricure (ATRC) had $167.4M in cash and equivalents against $61.9M in long-term debt.

Atricure (ATRC) had a gross margin of 75.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Atricure (ATRC) had an operating margin of -1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Atricure (ATRC) had a net profit margin of -2.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Atricure (ATRC) has a return on equity of -2.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Atricure (ATRC) generated $48.3M in free cash flow during fiscal year 2025. This represents a 6381.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Atricure (ATRC) generated $57.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Atricure (ATRC) had $654.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Atricure (ATRC) invested $9.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Atricure (ATRC) invested $99.2M in research and development during fiscal year 2025.

Atricure (ATRC) had 50M shares outstanding as of fiscal year 2025.

Atricure (ATRC) had a current ratio of 3.96 as of fiscal year 2025, which is generally considered healthy.

Atricure (ATRC) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Atricure (ATRC) had a return on assets of -1.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Atricure (ATRC) has an Altman Z-Score of 9.46, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Atricure (ATRC) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Atricure (ATRC) reported a net loss of $11.4M while generating $57.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Atricure (ATRC) reported an operating loss of $9.4M against $5.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Atricure (ATRC) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top